Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 8:13:929159.
doi: 10.3389/fphar.2022.929159. eCollection 2022.

Traditional chinese medicine in coronary microvascular disease

Zhihua Yang  1   2 , Shanshan Lin  1 , Yangxi Liu  1 , Qiuan Ren  1 , Zhao Ge  1 , Ci Wang  1 , Yingfei Bi  1 , Xianliang Wang  1 , Jingyuan Mao  1
Affiliations
Review

Traditional chinese medicine in coronary microvascular disease

Zhihua Yang et al. Front Pharmacol. .

Abstract

Coronary microvascular disease (CMVD) is common in patients with cardiovascular risk factors and is associated with an increased risk of adverse cardiovascular events. Although the study of CMVD in modern medicine is ongoing, there is still no effective treatment for it. Traditional Chinese medicine (TCM) has some clinical advantages based on syndrome differentiation and individualized treatment. In this review, we review the clinical significance, pathogenesis, and current treatments of CMVD and systematically summarize the clinical efficacy and potential action mechanisms of TCM for CMVD. In addition, the scientific problems that need to be solved urgently and the research strategy of TCM for CMVD are described. CMVD has great clinical significance, but there are still many gaps in the related research. This review aims to attract the attention of clinicians to CMVD and promote research on CMVD in TCM.

Keywords: clinical evidence; coronary flow reserve; coronary microvascular disease; coronary microvascular dysfunction; potential mechanism; traditional Chinese medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Development and research progress of CMVD.
FIGURE 2
FIGURE 2
Clinical evidence of TCM for CMVD.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Arroyo-Espliguero R., Kaski J. C. (2006). Microvascular dysfunction in cardiac syndrome X: The role of inflammation. CMAJ 174, 1833–1834. 10.1503/cmaj.051331 - DOI - PMC - PubMed
    1. Bai J., Wang X., Du S., Wang P., Wang Y., Quan L., et al. (2021). Study on the protective effects of danshen-honghua herb pair (DHHP) on myocardial ischaemia/reperfusion injury (MIRI) and potential mechanisms based on apoptosis and mitochondria. Pharm. Biol. 59, 335–346. 10.1080/13880209.2021.1893346 - DOI - PMC - PubMed
    1. Bairey Merz C. N., Handberg E. M., Shufelt C. L., Mehta P. K., Minissian M. B., Wei J., et al. (2016). A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): Impact on angina and myocardial perfusion reserve. Eur. Heart J. 37, 1504–1513. 10.1093/eurheartj/ehv647 - DOI - PMC - PubMed
    1. Bairey Merz C. N., Pepine C. J., Shimokawa H., Berry C. (2020). Treatment of coronary microvascular dysfunction. Cardiovasc Res. 116, 856–870. 10.1093/cvr/cvaa006 - DOI - PMC - PubMed
    1. Baumgart D., Haude M., Görge G., Liu F., Ge J., Grosse-Eggebrecht C., et al. (1999). Augmented alpha-adrenergic constriction of atherosclerotic human coronary arteries. Circulation 99, 2090–2097. 10.1161/01.cir.99.16.2090 - DOI - PubMed

LinkOut - more resources